NASDAQ$RPTX
Repare Therapeutics Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported financial results for the third quarter ended September 30, 2022.
Repare Therapeutics reported net income of $75.5 million, or $1.71 diluted earnings per share, and held $370.4 million in cash and cash equivalents and marketable securities as of September 30, 2022. The company believes this will be sufficient to fund planned operations into 2026.
- Early Phase 1 clinical data readout for RP-6306 is expected in the first half of 2023
- Camonsertib development is advancing with Roche under worldwide license and collaboration agreement
- IND-enabling studies for RP-2119, a Polθ inhibitor, are currently underway and on track for trial start in summer 2023
- Company is well positioned to advance clinical programs and portfolio, with $370.4 million in cash and cash equivalents and marketable securities and funding into 2026
Headline financials
Revenue & EPS history
Repare Therapeutics · Revenue · Quarterly
$113M
Forward guidance
Repare Therapeutics is focused on advancing its pipeline of programs and initiating clinical trials for new molecules.
Tailwinds
- Expected data readout for RP-6306 in the first half of 2023.
- Initiation of clinical testing of a new carboplatin combination with RP-6306 in 2023.
- Advancement of RP-2119, with clinical trials expected to start next summer.
- Initiation of IND-enabling studies for an additional small molecule in the first half of 2023.
- Collaboration with Roche for the development and commercialization of camonsertib.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports
+0.7%
Avg return
Earnings day
+3.3%
Avg return
5 days after
-0.1%
Avg return
30 days after
55%
12 / 22 earnings
Positive
+19.7%
Q2 2023
Best reaction
-13.5%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -2.4% | +27.5% | +26.3% | |
| Q2 2025 | +0.0% | +3.3% | +11.2% | |
| Q1 2025 | +3.8% | +0.0% | +9.1% | |
| Q4 2024 | -1.7% | +0.9% | -9.4% | |
| Q3 2024 | -0.6% | -4.4% | -13.5% | |
| Q2 2024 | -4.8% | -8.3% | -11.9% | |
| Q1 2024 | +11.5% | +7.7% | +17.4% | |
| Q4 2023 | +4.4% | -0.6% | -29.9% | |
| Q3 2023 | -6.6% | — | — | |
| Q2 2023 | +19.7% | — | — | |
| Q1 2023 | +1.5% | — | — | |
| Q4 2022 | +2.0% | — | — | |
| Q3 2022 | +7.7% | — | — | |
| Q2 2022 | +0.2% | — | — | |
| Q1 2022 | -9.2% | — | — | |
| Q4 2021 | +0.4% | — | — | |
| Q3 2021 | +2.2% | — | — | |
| Q2 2021 | -0.2% | — | — | |
| Q1 2021 | +0.5% | — | — | |
| Q4 2020 | -13.5% | — | — | |
| Q3 2020 | -2.3% | — | — | |
| Q2 2020 | +2.6% | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro